BR112013026004A2 - variantes de gdnf humano - Google Patents

variantes de gdnf humano

Info

Publication number
BR112013026004A2
BR112013026004A2 BR112013026004A BR112013026004A BR112013026004A2 BR 112013026004 A2 BR112013026004 A2 BR 112013026004A2 BR 112013026004 A BR112013026004 A BR 112013026004A BR 112013026004 A BR112013026004 A BR 112013026004A BR 112013026004 A2 BR112013026004 A2 BR 112013026004A2
Authority
BR
Brazil
Prior art keywords
human gdnf
variants
gdnf variants
human
gdnf
Prior art date
Application number
BR112013026004A
Other languages
English (en)
Other versions
BR112013026004B1 (pt
Inventor
Donmienne Doen Mun Leung
Jirong Lu
Kalpana Mahesh Merchant
Linda Maureen O Bryan
Mahmoud Ghanem
Rosamund Carol Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112013026004A2 publication Critical patent/BR112013026004A2/pt
Publication of BR112013026004B1 publication Critical patent/BR112013026004B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • External Artificial Organs (AREA)

Abstract

resumo patente de invenção: "variantes de gdnf humano". a presente invenção refere-se a novas variantes de fator neurotrófico derivado de células gliais humanas (gdnf) e a métodos para seu uso.
BR112013026004-1A 2011-04-11 2012-04-03 Variante de gdnf humano, sua composição farmacêutica e seu uso, bem como intermediário para uso na preparação da variante BR112013026004B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474024P 2011-04-11 2011-04-11
US61/474,024 2011-04-11
PCT/US2012/031927 WO2012141936A1 (en) 2011-04-11 2012-04-03 Variants of human gdnf

Publications (2)

Publication Number Publication Date
BR112013026004A2 true BR112013026004A2 (pt) 2016-11-29
BR112013026004B1 BR112013026004B1 (pt) 2020-09-29

Family

ID=45932578

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013026004-1A BR112013026004B1 (pt) 2011-04-11 2012-04-03 Variante de gdnf humano, sua composição farmacêutica e seu uso, bem como intermediário para uso na preparação da variante

Country Status (28)

Country Link
US (1) US9243046B2 (pt)
EP (1) EP2696889B1 (pt)
JP (1) JP6093345B2 (pt)
KR (1) KR101554799B1 (pt)
CN (1) CN103635201B (pt)
AU (1) AU2012243178B2 (pt)
BR (1) BR112013026004B1 (pt)
CA (1) CA2833158C (pt)
CY (1) CY1119750T1 (pt)
DK (1) DK2696889T3 (pt)
EA (1) EA025129B1 (pt)
ES (1) ES2656020T3 (pt)
HR (1) HRP20171993T1 (pt)
HU (1) HUE036239T2 (pt)
IL (1) IL228102A (pt)
LT (1) LT2696889T (pt)
ME (1) ME02849B (pt)
MX (1) MX337206B (pt)
NO (1) NO2696889T3 (pt)
PL (1) PL2696889T3 (pt)
PT (1) PT2696889T (pt)
RS (1) RS56639B1 (pt)
SG (1) SG193483A1 (pt)
SI (1) SI2696889T1 (pt)
TW (1) TWI583698B (pt)
UA (1) UA112981C2 (pt)
WO (1) WO2012141936A1 (pt)
ZA (1) ZA201306556B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018073300A2 (pt) 2016-05-13 2019-03-26 Instituto De Medicina Molecular métodos para tratamento de doenças associadas com as células ilc3
CA3162011A1 (en) * 2019-12-19 2021-06-24 Rodolphe SORET Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
JP2024522938A (ja) 2021-06-03 2024-06-21 フンダサン デー．アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド 脳－脂肪回路を介してｉｌｃ２および肥満度を制御する神経－間葉単位

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9205293A (es) 1991-09-20 1993-05-01 Syntex Sinergen Neuroscience J Factores neurotrofico derivado del glial
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
FI20070808A0 (fi) * 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
CN101775072B (zh) * 2008-05-21 2012-09-05 王尚武 一种融合穿透肽的神经细胞营养因子gdnf
EP2393832B1 (en) * 2009-02-06 2015-07-08 Pepscan Systems BV Truncated cystine-knot proteins

Also Published As

Publication number Publication date
UA112981C2 (uk) 2016-11-25
RS56639B1 (sr) 2018-03-30
LT2696889T (lt) 2018-02-12
NO2696889T3 (pt) 2018-04-14
ZA201306556B (en) 2015-03-25
CY1119750T1 (el) 2018-06-27
JP6093345B2 (ja) 2017-03-08
HRP20171993T1 (hr) 2018-02-09
EA025129B1 (ru) 2016-11-30
EP2696889A1 (en) 2014-02-19
CA2833158C (en) 2018-07-17
NZ614325A (en) 2015-07-31
SG193483A1 (en) 2013-10-30
CN103635201A (zh) 2014-03-12
IL228102A0 (en) 2013-09-30
KR20130131470A (ko) 2013-12-03
BR112013026004B1 (pt) 2020-09-29
KR101554799B1 (ko) 2015-09-21
US9243046B2 (en) 2016-01-26
US20130324474A1 (en) 2013-12-05
ES2656020T3 (es) 2018-02-22
ME02849B (me) 2018-01-20
SI2696889T1 (en) 2018-01-31
WO2012141936A1 (en) 2012-10-18
AU2012243178B2 (en) 2016-09-29
PT2696889T (pt) 2018-02-05
CA2833158A1 (en) 2012-10-18
CN103635201B (zh) 2016-11-09
DK2696889T3 (en) 2018-01-22
EP2696889B1 (en) 2017-11-15
MX2013011919A (es) 2014-03-27
EA201370204A1 (ru) 2014-02-28
IL228102A (en) 2017-04-30
HUE036239T2 (hu) 2018-06-28
TW201245220A (en) 2012-11-16
MX337206B (es) 2016-02-17
PL2696889T3 (pl) 2018-04-30
JP2014512369A (ja) 2014-05-22
TWI583698B (zh) 2017-05-21
AU2012243178A1 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
CL2015002567A1 (es) Compuestos y sus usos para modular la hemoglobina
ECSP11011276A (es) Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma.
CO7240369A2 (es) Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
CO7020878A2 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
ECSP14030742A (es) Proteínas del factor 21 de crecimiento del fibroblasto
ECSP14013224A (es) Pirimidinas anilladas sustituidas y uso de las mismas
BR112014029454A2 (pt) síntese de pirrolo [2,3-b] piridinas
CR20120596A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201491486A1 (ru) Производные пиперидинопиримидина для лечения вирусных инфекций
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
CO6400193A2 (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
WO2013151665A3 (en) Modified polynucleotides for the production of proteins associated with human disease
CR20140513A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112013023743A2 (pt) anticorpo de fator de tecidos humanos e usos do mesmo
BR112014028413A2 (pt) usos terapêuticos de proteínas do fator de crescimento de fibroblastos 21 .
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
BR112013029730A2 (pt) composição farmacêutica de rosuvastatina cálcica
EA201591133A1 (ru) СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
ECSP12012102A (es) Proceso para producir un extracto de alérgenos
BR112013030605A2 (pt) formulações orais de antioxidantes direcionados mitocondrialmente e preparação e uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/04/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2717 DE 31-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.